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Abstract: The epithelium of the lactiferous ducts in the breast is comprised of luminal
epithelial cells and underlying basal myoepithelial cells. The regulation of cell fate and
transit of cells between these two cell types remains poorly understood. This relationship
becomes of greater importance when studying the subtypes of epithelial breast carcinoma,
which are categorized according to their expression of luminal or basal markers. The
epithelial mesenchymal transition (EMT) is a pivotal event in tumor invasion. It is important
to understand mechanisms that regulate this process, which bears relation to the normal
dynamic of epithelial/basal phenotype regulation in the mammary gland. Understanding
this process could provide answers for the regulation of EMT in breast cancer, and
thereby identify potential targets for therapy. Evidence points towards a role for hedgehog
signaling in breast tissue homeostasis and also in mammary neoplasia. This review
examines our current understanding of role of the hedgehog-signaling (Hh) pathway in breast
epithelial cells both during breast development and homeostasis and to assess the potential
misappropriation of Hh signals in breast neoplasia, cancer stem cells and tumor metastasis
via EMT.
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1. Structure and Development of the Breast
The hedgehog pathway functions in controlling cell proliferation, cell fate, and patterning, as well as
stem and progenitor cell maintenance, self-renewal and tissue repair [1–5]. This pathway is critical for
homeostasis in mature tissue through the maintenance of somatic cell numbers within the organs of the
body [3,5].
The human breast contains two types of epithelial cells, referred to as epithelial and myoepithelial,
which form the mammary acini. These are linked to the branching ductal structures, forming the
tubular-alveolar gland. The tubular structures terminate at the nipple, and function to transport milk
produced in the acini. There is also a supporting stromal tissue, that is composed mainly of fat, known
as the fat pad, which surrounds these tubular-alveolar structures of the mammary gland [6].
During embryogenesis mammary tissue arises from the ventral ectoderm, formed as a result of
interactions between underlying mesenchymal cells and the epithelial cells of the ectoderm [7]. Breast
development has two distinct stages, the prenatal stage is summarized in Figure 1, and the postnatal
stage shown in Figure 2. Regulation of the embryonic stage of mammary development has not yet been
elucidated in its entirety. It has, however, been shown that hedgehog signaling is vital for the early
development of the mammary gland, with both sonic-(Shh) and Indian-hedgehog (Ihh) expressed and
required in mammary epithelium [7].
The mammary epithelium consists of several lineages; including luminal, alveolar and myoepithelial
cells. The normal mammary tissue contains both luminal and mesenchymal (or myoepithelial) stem cells,
responsible for renewal of the breast epithelium, as well as the massive expansion associated with cycles
of pregnancy [8]. Both luminal and mesenchymal stem cells are needed to form the normal structure
of the mammary gland. It has been demonstrated that transplantation of mesenchymal stem cells alone
leads to the production of both luminal and mesenchymal cell types (Figure 3), although the mechanism
for this is not clear [8].
The development of the mammary gland begins with the formation of a rudimentary ductal tree in
early embryogenesis, from the epithelial milk line, which is formed by the thickening of mammary
ridge epidermis along the ventral surface, however, the majority of breast development occurs after
puberty [4,9]. Hedgehog signaling is vital for the development of many organs in the body, including
the mammary gland. Hedgehog genes have an active role during every phase of breast development
both pre-and post-natal [5,10]. Figure 2 shows the cycle of postnatal breast development, with genetic
analysis in mice indicating a role for hedgehog signaling in mammary ductal morphogenesis, and in
human mammary epithelial stem cell self-renewal [4].
The function of Shh in the lactating breast has been reported to be restricted to paracrine,
inter-epithelial signaling, and no evidence has shown any autocrine function with the responding cells
found in the tissue adjacent to the secreting cells [11]. Furthermore, this paracrine signaling was
restricted to the surrounding responsive mature epithelial cells, and not the nearby mesenchymal cells,
which were unaffected.
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Figure 1. The prenatal stages of mammary gland tissue development. The mammary gland 
forms as early as day 10 of gestation in mice by the formation of the milk line. This is 
followed by at least four stages of development. At the time of birth the breast tissue is 
composed of three distinct layers including the mammary epithelium, mammary mesenchyme. 
(Which forms the structure of the secondary sprouts), and the dermis. Above are the 
expression patterns of active signaling and necessary for prenatal mammary gland formation. 
Illustrated in the top are the hedgehog components associated with those stages of 
development in mouse embryonic study. 
2. Breast Cancer Presents Either a Basal or Luminal Phenotype 
Breast cancer is the second leading cause of death in women worldwide, with one in eight women 
developing this disease, and is the most diagnosed cancer in females. It is classified histologically 
according tissue morphology, into ductal and tubular types, which is further divided into benign: ductal 
carcinoma in situ (DCIS); and lobular carcinoma in situ (LCIS), or invasive: invasive ductal carcinoma 
(IDC); and invasive lobular carcinoma (ILC) [12]. Breast cancer is further classified into luminal A/B, 
human epidermal growth factor receptor 2 (HER2)-enriched, basal-like (BL), and claudin-low [13]. 
Basal like breast cancer is classified in breast cancer cell lines into subtypes A (basal) and B 
(mesenchymal) [14]. Breast cancer is classified according to the expression of prognostic markers, 
including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) (Luminal A, Luminal B that are ER, PR, and HER2 positive), HER2 only positive, 
BL (expressing basal cytokeratin); triple negative (TN) (negative for all three receptors) [13].  
The basal and triple negative subtypes show considerable overlap (i.e. the majority of basal-type tumors 
are “triple negative” and vice versa). The percentage of each subtype presenting clinically as well as 
their associated prognosis is summarized in Figure 3. 
Figure 1. The prenatal stages of mammary gland tissue development. The mammary
gland forms as early as day 10 of gestation in mice by the formation of the milk line.
This is followed by at least four stages of development. At the time of birth the breast
tissue is composed of three distinct layers including th mammary epithelium, mam ary
mesenchyme. (W ich forms the s ructure of the ec ndary sprouts), and the dermis. Above
are the expression patterns of active signaling and necessary for prenatal mammary gland
formation. Illustrated in the top are the hedgehog components associated with those stages
of development in mouse embryonic study.
2. Breast Cancer Presents Either a Basal or Luminal Phenotype
Breast cancer is the second leading cause of death in women worldwide, with one in eight women
developing this disease, and is the most diagnosed cancer in females. It is classified histologically
accordi g tissue morphology, into ductal and tubular types, which is further divided into benign:
ductal carcinoma in situ (DCIS); and lobular carcinoma in situ (LCIS), or invasive: invasive ductal
carcinoma (IDC); and invasive lobular carcinoma (ILC) [12]. Breast cancer is f rther classified
into luminal A/B, human epidermal growth factor rec ptor 2 (HER2)-enriched, basal-like (BL), and
claudin-low [13]. Basal like breast cancer is classified in breast cancer cell lines into subtypes A
(basal) and B (mesenchymal) [14]. Breast cancer is classified according to the expression of prognostic
markers, including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth
factor receptor 2 (HER2) (Luminal A, Luminal B that are ER, PR, and HER2 positive), HER2 only
positive, BL (expressing basal cytokeratin); triple negative (TN) (negative for all three receptors) [13].
The basal and triple negative subtypes show considerable overlap (i.e. the majority of basal-type tumors
are “triple negative” and vice versa). The percentage of each subtype presenting clinically as well as
their associated prognosis is summarized in Figure 3.
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Figure 2. Postnatal mammary gland development is composed of several stages (after birth, 
puberty, adult, pregnancy, lactation, involution, and menopause). Highlighted are the known 
key hedgehog signaling components expression found essential at each stage of mammary 
adult female breast. It should be noted that other Hh components are found expressed at 
various stages, yet the highlighted compounds are the ones found important for that stage of 
development. 
3. The Components of Hedgehog Signaling Pathway 
Hedgehog signaling may be transduced by two distinct mechanisms, known as the canonical and  
non-canonical pathways (both summarized in Figure 4). The canonical pathway (Figure 4A) depends on 
the interaction between hedgehog ligands from the secreting cells and the Patched (Ptch) receptor on 
another cell. This interaction then releases the Ptch-mediated inhibition of the Smoothened (Smo) 
complex, initiating signal transduction in the receiving cell. This results in release of the activated form 
of Gli (Gli-A in Drosophila which correspond to Gli-1 in mammals), which translocates to nucleus, 
where it acts as transcriptional regulator. It has been shown that both Gli-1 and Ptch-1 provide regulatory 
negative feedback of the cascade [15]. 
In addition to the canonical Hh signaling pathway, a non-canonical Hh pathway was recently  
reported [16,17]. This alternate mechanism involves activation of the hedgehog pathway components by 
other signaling cascades such as that associated with the epidermal growth factor receptor (Figure 4B). 
Figure 2. Postnatal mammary gland development is composed of several stages (after birth,
puberty, adult, pregnancy, lactation, involution, and menopause). Highlighted are the known
key hedgehog signaling components expression found essential at each stage of ma mary
adult female breast. It should be t t t t r co ponents are found expressed at
various stages, yet the hig li pounds are the ones found impor ant for th t stage
of l ent.
3. The Components of Hedgehog Signaling Pathway
Hedgehog signaling may be transduced by two distinct mechanisms, known as the canonical and
non-canonical pathways (both summarized in Figure 4). The canonical pathway (Figure 4A) depends
on the interaction between hedgehog ligands from the secreting cells and the Patched (Ptch) receptor
on another cell. This interaction then releases the Ptch-mediated inhibition of the Smoothened (Smo)
complex, initiating signal transduction in the receiving cell. This results in release of the activated form
of Gli (Gli-A in Drosophila which correspond to Gli-1 in mammals), which translocates to nucleus,
where it acts as transcriptional regulator. It has been shown that both Gli-1 and Ptch-1 provide regulatory
negative feedback f the scade [15].
In addition to the c nonical Hh signal g pathway, a n-canonical Hh pathway was recently
rep rted [16,17]. This alternate mechanism involves activation of the hedgehog pathway components by
other signaling cascades such as that associated with the epidermal growth factor receptor (Figure 4B).
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Figure 3. The mammary gland stem cell types and the corresponding breast cancer type. (a) 
The expansion of breast cell types from a single progenitor; (b) The molecular sub 
classification of breast cancers, their hypothesized origin, and percentage prevalence at 
clinical presentation; (c) The involvement of EMT process in breast cancer and a suggested 
level of EMT according to the sub classification of breast cancer; (d) The associated 
prognosis of various breast cancer subtypes. 
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Figure 3. The mammary gland stem cell types and the corresponding breast cancer type.
(a) The expansion of breast cell types from a single progenitor; (b) The molecular sub
classification of breast cancers, their hypothesized origin, and percentage prevalence at
clinical presentation; (c) The involvement of EMT process in breast cancer and a suggested
level of EMT according to the sub classification of breast cancer; (d) The associated
prognosis of various breast cancer subtypes.
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Figure 4. The Hedgehog signaling pathway. (A) The canonical hedgehog signaling 
components, the secreted ligands (Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and 
Desert Hedgehog (Dhh)) and the Patched family hedgehog receptors Patched-1 (Ptch-1) and 
Patched-2 (Ptch-2). Both patched receptors antagonize the function of the Smoothened 
(Smo) transmembrane effector protein in the absence of the ligand, therefore inhibiting the 
expression of one or more of the Gli (Glioma-associated oncogene homologue) family of 
transcription factors (Gli-2 or Gli-3) [1,4,5,18]. In the absence of ligand, Gli is sequestered 
in the cytoplasm by binding to form a large complex protein with the Kinesin-like Costal2 
and the serine-threonine kinase Fused [1,2,4,15,18]; (B) Hedgehog signaling can be 
activated through three known non-canonical pathways, including Shh-mediated ERK 
activation in mammary epithelial cells, Wnt signaling pathway involvement in the 
expression and function of Gli proteins, and the atypical interaction of core Hh pathway 
components with each other [15–17]. 
4. Hedgehog Signaling in Physiologically Normal Pre- and Post-natal Mammary Gland 
Kameda et al. demonstrated patterns of Hh signaling during development by studying disruption of 
their function. Knock-out animal models and transplantation studies in the mouse have shown that 
hedgehog signaling plays a critical role in ductal development in the mammary gland [2]. 
Mammary gland tissue arises in embryogenesis as a result of interactions between underlying 
mesenchymal cells and epithelial cells of the ectoderm, but the regulation of this process in human 
embryogenesis is not entirely clear [7]. Michno et al. showed that hedgehog signaling is vital for 
mammary gland development in animal models. Both Shh and Ihh are expressed during breast tissue 
development, where they are expressed exclusively in the mammary epithelium. Furthermore, when one 
of these genes was knocked-out the other was able to compensate for its absence [7]. Gritli-Linde et al. 
showed that the mammary gland shares a common progenitor with the hair follicle, both arising from 
the dermis. Knocking down Shh in the earliest hair follicle progenitor tissue results adoption of a 
mammary gland fate, and knocking down Ihh in the early stages does not affect hair follicle development 
Figure 4. The Hedgehog signaling pathway. (A) The canonical hedgehog signaling
components, the secreted ligands (Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and
Desert Hedgehog (Dhh)) and the Patched family hedgehog receptors Patched-1 (Ptch-1)
and Patched-2 (Ptch-2). Both patched receptors antagonize the function of the Smoothened
(Smo) transmembrane effector protein in the absence of the ligand, therefore inhibiting the
expression of one or more of the Gli (Glioma-associated oncogene homologue) family of
transcription factors (Gli-2 or Gli-3) [1,4,5,18]. In the absence of ligand, Gli is sequestered
in the cytoplas by binding to for a large co plex protein with the Kinesin-like Costal2
and the serine-threonine kinase Fused [1,2,4,15,18]; (B) Hedgehog signaling can be activated
through three known non-canonical pathways, including Shh-mediated ERK activation in
mammary epithelial cells, Wnt signaling pathway involvement in the expression and function
of Gli proteins, and the atypical interaction of core Hh pathway components with each
other [15–17].
4. Hedgehog Signaling in Physiologically Nor al Pre- and Post-natal a ary Gland
Kameda et al. demonstrated patterns of Hh signaling during development by studying disruption
of their function. Knock-out animal models and transplantation studies in the mouse have shown that
hedgehog signaling plays a critical role in ductal development in the mammary gland [2].
Mammary gland tissue arises in embryogenesis as a result of interactions between underlying
mesenchymal cells and epithelial cells of the ectoderm, but the regulation of this process in human
embryogenesis is not entirely clear [7]. Michno et al. showed that hedgehog signaling is vital for
mammary gland development in animal models. Both Shh and Ihh are expressed during breast tissue
development, where they are expressed exclusively in the mammary epithelium. Furthermore, when one
of these genes was knocked-out the other was able to compensate for its absence [7]. Gritli-Linde et al.
showed that the mammary gland shares a common progenitor with the hair follicle, both arising from the
dermis. Knocking down Shh in the earliest hair follicle progenitor tissue results adoption of a mammary
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gland fate, and knocking down Ihh in the early stages does not affect hair follicle development [9].
On the other hand, knocking-down Shh does not affect the early development of mammary gland. Thus,
suggesting that Ihh is the key regulator in early development of epithelial tissue of the mammary gland,
whereas absence of Shh is apparently important for tissue to follow hair follicle fate. Additionally, Shh
knockout mice, though die prematurely as Shh is vital for development, has normal uninterrupted breast
development in all embryonic stages. One of the earliest known markers for mammary bud formation,
Lef-1, was unchanged in the absence of Shh [7]. The expression of cyclin D1, a target of the Hh pathway,
in Shh-deficient mice was unaltered compared with that of wild type mice [7].
Ptch-1 is expressed in both the epithelial and mesenchymal tissue of the developing mammary gland
and is essential in mammary morphogenesis [7]. Heterozygous Ptch-1-deficient mice developed ductal
hyperplasia and dysplasia during puberty and virginal adulthood, mainly in ductal structures, with minor
defects associated with terminal buds [5,7]. This dysplasia reversed during pregnancy and lobuloalveolar
structures matured to facilitate lactation. Lewis et al. showed that high expression of Ihh during
pregnancy and lactation compensated for absence of Ptch-1 (Figure 2). Then, the tissue exhibited
dysplasia after involution and breast remodeling, [5], where Ptch-1 expression becomes undetectable
2 days after involution. Furthermore, staining of the dysplasia showed that it did not reach myoepithelial
tissue, suggesting the function of Ptch1 is restricted to areas adjacent to the dysplastic epithelial tissue,
no detectable expression was seen distant from epithelial cells [5]. Michno et al. showed that Ptch-1 was
required in the mesenchymal tissue and not in the epithelial cells, as transplantation of epithelial cells
from Ptch-1 haploinsufficient mice to wild type mice led to formation of normal mammary ducts [4,7].
Also, increased expression of activated human Smo-2 in transgenic mice leads to increased proliferation,
altered patterns of differentiation, and ductal dysplasia that is distinct from the pattern associated with
Ptch-1 heterozygosity [4].
Various studies have shown the importance of Gli transcription factors, the downstream effectors of
Hh signals, in mammary gland development in the embryo. Gritli-Linde et al. showed that transplantation of
Gli-2 knock-down epithelial cells into wild type fat tissue resulted in normal growth of mammary tissue,
suggesting that the required Hh signaling arises from the underlying mesenchymal tissue [7]. A recent
study reported that Gli-3 is required during the early stages of mammogenesis, and Gli-1 transcription
and Gli-2 function were antagonized early in development of the breast [15]. The data published by
both Lee et al. and Michno et al. suggested that there was a differential requirement for Gli activity
between mammary epithelium and mesenchyme, as they reported that Gli-2 and Gli-3 were expressed
in later stages of embryological development [7,15]. However, the effect of expression of one Gli family
member on the expression of the others has not been clarified yet.
In the normal mammary tissue of mice, the expression of Shh, Ihh, and Dhh have been identified by
RT-PCR, and only Ihh expression was detected by in situ hybridization, where it was expressed near
the terminal buds at the point where the ducts branch [7]. Patch-1 was expressed in the epithelial cells
as well as the fibroblasts in surrounding mesenchymal tissue [7]. Undifferentiated luminal epithelial
cells of terminal end buds were expressing higher levels of Ptch-1 compared with the mesenchymal
stem cells. During puberty, the pattern of expression of Ptch-1 is restricted to the terminal end buds,
illustrating its key role in the regulation of mammary ductal tree growth [5]. Gli-2 protein is expressed
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in the mesenchymal cells near the end buds during puberty, and in early pregnancy, whereas in the later
stages of pregnancy it is expressed in the alveolar epithelial cells [7].
Therefore, there is a clear requirement for Hh signaling in the mammary gland. Certain components of
the Hh pathway are important in early breast development, and disturbance of this pattern of expression
was associated with abnormalities including dysplasia. Thus suggesting a potential role for Hh in the
regulation of homeostasis and therefore, potentially, neoplastic transformation.
5. Hedgehog-Signaling Pathway in Breast Cancer
Hedgehog signaling is altered in nearly 25% of all human cancers [1,3–5]. There is evidence in
the literature that the proliferative capacity of various cancer cell lines is reliant, at least in part, on
Hh signaling [2,19], and some studies have suggested that Hh signaling plays a key role in tumor
cell invasion [2,18]. Dysregulation of the pathway has been linked with the formation and malignant
progression of lung, breast, pancreatic and prostate cancer [4,18]. Hh signaling has now also been
shown to be associated with the invasion of many cancer cell types including those showing mutational
activation of the pathway such as basal cell carcinoma of the skin, and medulloblastoma [2,5]. Recent
studies have also linked Hh with invasion in other solid tumors, such as those of the stomach, ovary and
lung [2,5,20–22].
Hedgehog signaling has been demonstrated to contribute to early breast cancer development by
increasing tumor cell proliferation [4], although prior to 1999 there were no published studies on the
presence or role of Hh signaling in breast cancer. Ptch-1 mutations were identified in a small proportion
of breast cancers at that time [5]. Zhang et al. reported evidence that dysregulation in hedgehog signaling
may contribute to breast cancer development in an animal model [1]. In 2009 it was reported that
activation of the Hh pathway is a common feature in breast carcinoma, a finding also confirmed in
later studies [2,3]. Mutations in Ptch-1 and Gli-2 genes in mouse models resulted in abnormalities
in mammary ductal morphogenesis, including hyperplasia that resembled hyperplasia in humans [2].
In the initial studies, little or no evidence of a connection between mutations in the Hh signaling pathway
and breast cancer was reported, with no mutations in either Shh, Ptch-1, or Smo [23,24], confirming the
earlier work showing that mutational Hh pathway activation was uncommon in these tumors. Table 1
shows a summary of the published reports investigating Hh pathway mutations in breast cancer, with
rare somatic mutations of Gli-3 also published [15]. It should be emphasized here that even though Hh
pathway mutations are rare in breast cancer, similar to many of the other common human malignancies, it
has been demonstrated that this pathway is important the pathogenesis of many human cancers including
colon cancer [19].
Mutations are not the only mechanism by which Hh signaling can promote cancer. Misappropriation
of Hh signaling, that is increased or decreased pathway activation is frequently seen in human cancers,
such as colon cancer [19]. Therefore, for the purpose of this review, this group of signaling defects
will be further discussed. Localization of some of the Hh signaling components, Gli in particular, is
important to determine the functional status of the pathway. For example, localization of Gli in the
nucleus indicates functionally active Hh signaling (Table 2).
Cancers 2015, 7 1871
Table 1. Mutations in hedgehog signaling pathway associated with breast cancer.
Type of Mutation Study Genes
Finding in Breast
Cancer Studies
Ref.
Missense mutation Mice SHH 1/6 mice developed cancer [25]
Missense mutation Human DNA compared to normal tissue Ptch-1 2/7 breast carcinoma [26]
Missense mutations
Human breast cancer cell lines and
primary breast tumors
Gli-1
2/24, 8% breast cancers 9%
breast cancer cell lines
[27]
Loss of chromosomal region
Human breast cancer cell lines and
primary breast tumors
Ptch-1
19% of primary breast cancers
33% breast cancer cell lines
[28]
Polymorphism Human clinical samples Ptch-1 [29]
Table 2. Expression of hedgehog in breast cancer.
Hh Component
Expression in Breast Cancer
Compared to Normal
Study and Reference
Gli-1 mRNA and protein 40%–100% Increase
Cell lines and Human clinical samples [30]
Cell lines [31]
Cell lines compared to human mammary epithelial cells (HMEC) [32]
Human tissue from primary tumors and metastasis site [33]
Human tissue from primary tumors [34]
Breast cancer cell line [35]
Human clinical samples [36]
Ptch-1 mRNA and protein
40% Decrease;
50%–58% Decreased protein or
33%–96%increase
Cell lines [31]
Breast cancer cell lines [37]
Human clinical samples and transgenic mice [4]
Breast cancer cell lines and clinical samples [38]
Clinical samples and cell lines [30]
Cell lines and clinical samples [31]
Human clinical samples [36]
Human sample from primary tumors [34]
Breast cancer cell lines [35]
Smo mRNA and protein 30%–70% Increase
Transgenic mice and clinical samples [4]
Cell lines and clinical tissue [31]
Human samples from primary tumor [34]
Breast cancer cell lines [35]
Human clinical samples [36]
Shh Protein and mRNA 63%–100% Increase
Cell lines and Human clinical samples [30]
Cell lines and clinical tissue [31]
Human samples from primary tumor [34]
Breast cancer cell lines [35]
Human clinical samples [36]
In 2008, alternative splice isoform of Gli1 was identified (GLI∆N), with wild type GLI1 full-length
(GLI1FL) expression was more abundant in the nucleus than this isoform [39]. The activation capacity
of GLI1∆N was reported to be more than that of GLI1FL though the latter is found more concentrated
in the nucleus. Later in 2009, another splice variant was identified and was called truncated GLI1
(tGLI1) [40]. A growing body of evidence suggests that there is variation in expression pattern of
these different isoforms, and that there is a difference in their ability to regulate gene activation [40,41].
These differences lead to changes in cellular behavior including proliferation, migration, invasion,
angiogenesis, and metastasis. The structure and regulation of the GLI1 isoforms by Hh signaling
pathways have been reviewed previously [42,43]. tGLI1 was reported to be frequently expressed in
human breast cancer cell lines and primary breast cancer specimens, but was not detectable in normal
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breast tissue [41]. It has been shown to upregulate vascular endothelial growth factor-A (VEGF-A),
thereby stimulating angiogenesis. Also, tGLI1 enhanced the ability of breast cancer cells to migrate
and invade, by facilitating anchorage-independent growth [41]. These findings are supported by a later
report showing increased expression of tGLI1 supporting tumor angiogenesis and aggressive growth in
glioblastoma [44].
Various reports show that this type of inappropriate activation of Hh signaling also occurs in breast
cancer. The Ptch promoter is methylated in some breast cancer cell lines, and this correlates with low
Ptch expression [38]. Gli-1 upregulation correlates with poor prognosis of triple negative and basal like
breast cancers. Limited Gli-3 mutations are limited and not reported in cancer samples [15] and over
expression of Gli-1 is associated with poor prognosis [45].
There is debate in associating Hh deregulation within the various subtypes of breast cancer. Hh
signaling was shown significantly higher in invasive ductal carcinoma compared with non-invasive
ductal carcinomas (DCIS). In 2009, a group of researchers in Japan showed that Hh is constitutively
activated in surgically resected ER-receptor negative breast cancers [2]. Nuclear localization of Gli-1
was detected in both ER-positive as well as ER-negative cases, and suggested the exploitation of Gli-1
as target for therapy [2]. Quantitative analysis using Real-Time RT-PCR on clinical samples, containing
4 Triple Negative and Basal-Like breast cancer as well as six HER2 positive cases, showed higher Gli-1
expression in tumors compared with matched normal tissue. With ER-receptor status being significantly
associated with Hh activity. Whereas Gli-1 and Ptch-1 mRNA and protein are expressed in triple negative
breast cancer cell lines [2]. Knocking down Gli-1 in in two ER receptor negative cell lines, one triple
negative and one basal resulted in significantly reduced proliferation in both cell lines [2]. Knock down
of Gli-1 or inhibition of Smo, by the plant-derived inhibitor cyclopamine, resulted in decreased invasive
capability in these cell lines. Table 2 summarizes the published reports of Hh pathway expression in
breast tumors However, it is worthy of note that differences in expression of Hh signaling between the
different molecular classifications of breast cancer was not factored into most of these studies.
Zhang et al. recently showed that inhibition of Hh signaling with cyclopamine resulted in decreased
growth of breast cancer cells in vitro [1]. The same study showed altered expression of hedgehog network
genes in clinical samples and breast cancer cell lines, showing active Smo-mediated signaling. It has also
been reported that it was not only Gli-1 that was important for breast cancer prognosis but also that there
was increased expression of Shh [45] which has been shown to contribute to tumor cell survival [31].
Other studies have shown decreased, or even loss of, Ptch-1 expression in almost 50% of breast
cancer cases—with increased Smo detected in approximately 70% of ductal carcinoma in situ (DCIS)
and 30% of invasive breast carcinoma [1,4]. Expression of Shh, Ptch-1, Gli-1, and Smo mRNA in breast
cancer tissue was also shown to correlate with disease recurrence.
With the exception of Gli-1, all other pathway members were significantly correlated with the size of
the tumor, and Smo was associated with lymph node involvement [34,46]. Thus, these studies related
signs of tumor aggression with elevated levels of Hh pathway expression. These findings have been
corroborated by other work [30,47], although contradictory data has also been reported by another
group [48]. This apparent controversy can be explained by the different approaches used in the selection
of cases and in the detection methods employed.
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Recent in vitro cell line studies provide more insight into the association of Hh signaling with breast
cancer. Gli-1 mRNA level was increased in a number of breast cancer cell lines, including MDA-MB-453
(TN), MDA-MB-231 (TN and basal type B), BT20 (basal type A), MCF10A (benign breast cancer cell
line) and SKBR3 (HER2+) in comparison to a primary human mammary epithelial cells (HMEC) [45].
Gli1 protein expression was significantly higher in two TN and basal cell type B cell lines compared with
HMECs. Gli-1 siRNA treatment of these cells resulted in decreased cell proliferation with a concomitant
increase in apoptosis, and Gli-1 knock down also resulted in a significant reduction in the migratory
ability of these cells [32]. These data suggest an important role for Hh signaling in maintaining tumor
cell survival in breast cancer.
In vivo, Gli-1 overexpression correlates with unfavorable overall survival in patients, tumor stage, and
lymph node involvement [45]. Furthermore, activation of Gli-1 was independent of Hh-ligands and does
not depend on Smo either, which signposts a potential alternative pathway of activation (Figure 4B) [32].
A previous study showed that Shh genes predicted poor clinical outcome in inflammatory breast cancer
patients using microarray analysis [49]. Cell lines derived from inflammatory breast cancers have
activated EGFR that similarly points toward alternative activation of Hh through the non-canonical
pathway (Figure 4B). These data suggest that Hh could also play a key role in the progression of breast
cancer, and may be useful prognostic indicator.
Gli-1 is also expressed in normal breast tissue, suggesting that Gli-1 is involved in regulation of
normal breast cell behavior [45,50]. This result remains a debated topic and some studies reported
no Gli-1 expression at all in normal breast epithelium [30]. This could be due to variations in tissue
sampling, or in the threshold of detection for the protocol used. It may prove beneficial to include
comparison of the molecular subtypes of breast cancer in future studies, and this approach could answer
the debate about involvement of Gli-1. To this end, a recent study showed that nuclear localization of
Gli-1 was associated with the hormone receptor negative, basal-like breast cancer group [50]. Also,
it was reported in this study that there was nuclear and cytoplasmic localization of Gli-1 in a small
percentage of basal epithelial cells of normal breast tissue. Thus, supporting notion that expression of
Gli-1 is expressed in normal breast tissue and that its location in a small percentage of particular cell
type and explaining the current question mark over its expression in normal tissue.
Further evidence for differing Hh patterns within the different breast cancer subgroups was illustrated
by the finding of Gli-1 and Smo overexpression in TN breast cancer cases and a positive correlation with
increased tumor stage. This was offset by an inverse correlation with estrogen receptor (ER) expression,
again suggesting subtype-specific expression patterns [36]. In vitro studies of Gli-1 have shown high
levels of expression in SUM145 cells, which are basal type B as well as triple negative, yet it was not
increased in other triple negative and basal-like breast cancer lines, including MDA-MB-231. Thus,
suggesting that other factors contribute to high Gli-1 expression in these cells [32]. On the other hand
Gli-1 expression was lower in the ER-positive breast cancer cell lines T47D and MCF7 [36]. Studies of
Gli-1 in vivo report increased expression in four out of five paired normal and tumor clinical samples,
which was not statistically significant, which could be due to small sample size [45]. They, and others,
have observed increased nuclear localization of Gli-1 in breast cancer samples compared to normal breast
tissue, yet there was agreement in two studies that strength of expression of Gli-1 varied significantly
among breast cancer samples [30,45].
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The localization of Gli-1, nevertheless, has raised a debate over its overexpression and the presence
or absence of hormone receptors in breast cancer [30,45,50], with some studies reporting a correlation
between the nuclear localization of Gli-1 and ER status [30], some linking Shh expression and ER-alpha
in particular [51,52]. Others suggest that this pathway presents a potential target in ER-negative
carcinomas [2]. Jeng et al. in 2014 reported that they did not find a correlation between Shh and ER
or progesterone receptor (PR), but it was related to Her-2 overexpression [34]. Another group reported
a correlation between ER and Ptch expression and that Ptch polymorphisms are linked to cancer risk
associated with oral contraceptive use [38].
Ptch-1 was shown to be increased significantly in luminal breast cancer cell lines MCF7, T47D,
13762 and HER2+ cell line SKBR3 [37]. Ptch-1, on the other hand, was reported to regulate cell
cycle progression and high expression of Ptch-1 has been associated with metastasis in many human
cancers [53]. It was observed that expression of Ptch-1 was significantly decreased in breast cancer
compared to mammary hyperplasia [36]. A study suggested that the mRNA of Ptch-1 and Gli-1 in core
needle biopsy would provide a useful tool for surgeons and patients for the selection of treatment options
in the clinical management of breast cancer [34].
Recently, a study reported that increased expression of a liver kinase B1 (LKB1) in breast cancer
cell lines inhibits Hh signaling, as well as decreasing the rate of growth of the cell lines in a xenograft
model. This study determined that LKB1 controls cellular proliferation and induces programmed cell
death. Conversely, LKB1 knock down in the same cells resulted in significant activation of the Hh
pathway and a significant increase in xenograft growth of these cells when injected into mice [18].
LKB1 antagonized the function of Hh protein expression in MDA-MB-231 cells and cells with active
Hh signaling have decreased or non-detectable LKB1, therefore, suggesting that LKB1 is a negative
regulator for Hh [18]. Staining of histological clinical specimens of ductal carcinoma cases revealed
that there is high expression of LKB1 in 44% of cases and that the expression of this protein negatively
correlates with Shh, Gli-1, and Smo, while there was no observed correlation with Ptch [18]. There
appears to be some contradiction amongst the reported levels of expression of Ptch-1, as mentioned
previously. This apparent variation in findings may be due to different locations from which biopsies
were selected, as well as variation in the method of investigation.
Target genes for Gli transcription factors include Ccnd 1, Bcl-2 and members of the Myc gene
family, which affect cell cycle, survival, proliferation, stem cell activation, as well as metastasis [54].
High levels of Ccnd1 were reported in GLI1-induced highly proliferative mammary gland lesions [55].
Another target gene called BCL-2 is commonly found up-regulated in human tumors including breast
cancer [56,57]. Also, the transcription factor Snail is elevated after ectopic expression of GLI1 in the
mouse mammary gland, which leads to loss of E-cadherin expression, thus promoting EMT, discussed
later [58].
Taken together, these data suggest an important role for Hh signaling in breast cancer development
and progression. What is not yet clear, however, is how Hh activation relates to the specific tumor
subtypes, and therefore how this could impact on prognosis. A key issue affecting patient survival is
disease recurrence. In recent years we have come to understand the importance of cancer stem cells
(CSCs) in the ability of a tumor to return following treatment. Although the study of CSCs has yielded
a wealth of data and understanding, many questions remain unanswered. Hh signaling is known to
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modulate the stem cell phenotype in a number of tissues and, as described above, has been implicated in
stem cell maintenance in healthy breast tissue. The role of Hh in breast CSCs is not yet clear.
6. Breast Cancer Stem Cells
A recent study reported that normal mammary tissue has two distinct types of stem cells
(see above) [8]. The molecular sub-classification of breast cancer identified five major subtypes of
breast tumors, as indicated previously, and each of these sub-classifications have significantly different
prognosis and treatment strategies and, as each presents with a different cellular phenotype, it is possible
that they potentially arise from different progenitor cells [59].
To facilitate studying the behavior of mammary stem cells it is necessary to have available an in vitro
model. Human mammary epithelial cells (HMECs) have been successfully cultured and provide a model
to study mammary stem cells, retaining the ability to undergo the stem cell-like epithelial mesenchymal
transition [59].
It has been hypothesized that continuous activation of Shh may neoplastically transform breast stem
cells and be associated with a poor cancer prognosis [36]. A later study suggested that the activation of
Shh pathway was not only vital in early stages of tumorigenesis by initiating aberrant stem cell growth,
but is also important for subsequent cancer progression and recurrence [34]. Moreover, it was reported
that there were luminal progenitor cells in a population of luminal epithelial cells that are Hh-sensitive
in the breast as well as basal progenitor cells in that population [11]. Hh signaling is important for
progenitor cell proliferation and differentiation [60] and misappropriation of the Hh signaling pathway
in this population of cells may lead to increased progenitor growth and subsequently lead to cancer [11].
High levels of SMO and Gli-1 expression have been found to correlate with continuous activation
of breast cancer stem cells in TNBC patients samples [36]. Furthermore, another recent study reported
that inhibition of NFκB significantly reduced Gli-1 expression and protein levels in breast cancer cell
lines BT549, HS578T, MDA-MB-231, MDA-MB-157, MDA-MB-436, as well as MCF10A [61], and
suggested that Gli-1 functions in the maintenance and regulation of cancer stem cells.
7. Hedgehog in the Regulation of EMT in Breast Cancer
It is now widely accepted that the epithelial-mesenchymal transition (EMT) plays an essential role
in the metastatic spread of many tumor types, including breast cancer. During localized invasion
and subsequent metastasis, cancer cells lose their epithelial characteristics including cell-cell adhesion
and polarity markers, and gain mesenchymal characteristics that allow them to become motile and
invade neighboring tissue [62,63]. EMT has been linked to the progression of many human epithelial
malignancies including: pancreatic [64], lung [65], cervical [66], and colon cancer [67].
Shh up-regulation in tumors is thought to impact on the tumor microenvironment [34] resulting
in the formation of activated stroma, which responds to tumor-derived Hh ligands [11,68]. This is
different from normal breast tissue in which the nearby mesenchymal cells do not respond to Hh signals
originating from active epithelial cells (described above).
It has been shown that the Wnt signaling pathway is involved in the regulation of breast progenitor
cell proliferation. Hh and Wnt classically act together, and reciprocally, to regulate cell behavior across
epithelial-mesenchymal boundaries in both the developing embryo and in adult tissues. Recent work has
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shown that misappropriation of both Wnt and Hh signaling between epithelial progenitors and adjacent
mesenchymal cells leads to mammary tissue hyperplasia in a mouse model [11]. Hh and Wnt have also
been shown to be important mediators of EMT, both in the developing embryo and in tumor progression.
Key features of EMT include the loss of expression of the cell-cell adhesion molecule E-cadherin and
expression of transcription factors such as Slug and Snail. In SUM145 cells (basal type B), it has
been shown that Gli-1 inhibits E-cadherin expression. However, Gli-1 did not affect the levels of the
transcription factor Snail, a known repressor of E-cadherin, suggesting an alternate mechanism [32].
The authors suggest that further investigation of the mechanism of Gli-1-mediated E-cadherin regulation,
and the relationship to EMT, is required [32].
8. Potential Therapeutic Targeting of the Hedgehog-Signaling Pathway
As our understanding of the role of Hh in human disease, particularly cancers has increased, there
has been great interest in targeting this pathway therapeutically. There are several naturally-occurring
substances with an ability to antagonize hedgehog signaling, and a number of hedgehog antagonists
have been synthesized (Figure 4). The widely used hedgehog inhibitor cyclopamine belongs to a
group of plant-derived alkaloids, first identified for their teratogenic activity in sheep [1]. Cyclopamine
acts through direct binding to Smo, therefore, inhibiting the downstream canonical Hh signaling
pathway [69]. It has also been shown to inhibit the non-canonical Akt pathway, although the precise
mechanism for this is not clear [3,70]. In vitro studies in other tumor types have also shown promise,
such as the demonstration of cyclopamine-induced apoptosis in colon cancer cells [19].
Recently, a study reported that the diabetes drug metformin lowered the risk of certain types of
cancers, by inhibiting the Shh signaling pathway [35]. Furthermore, this drug inhibited breast cancer
cell migration and invasion as well as cancer stem cell survival and self-renewal, accompanied by a dose
dependent decrease in the levels of several Hh components. Studies in mice of with other hedgehog
inhibitors showed minor or non-significant side effects, thus, highlighting their potential use in treatment
of cancer [70].
Cyclopamine has been shown to inhibit cellular proliferation in a dose-dependent manner in the breast
cancer cell line MDA-MB-231 (triple negative, basal type B) [2]. Others have investigated the use
of cyclopamine in combination with paclitaxel, commonly used in breast cancer chemotherapy. They
reported that this combination resulted in increased tumor cell line apoptosis compared to paclitaxel
treatment alone [71]. Furthermore, this study also showed that blocking hedgehog resulted in loss of
tumor stem cell maintenance and led to reduction of cancer stem cell-related chemotherapy resistance.
Another study in the same year reported that cyclopamine works as a novel, potent inhibitor of the
proliferation of breast cancer cell lines and reduced expression of ER in ER-positive cells [3]. Both
MCF7 and MDA-MB-231 cell lines (ER-positive and ER-negative, respectively), displayed significant
reduction in growth following cyclopamine treatment [3]. Cyclopamine arrested the cells in the G1 phase
of the cell cycle by interrupting cyclin D1 production through modulation of the MAPK/ERK signaling
pathway. Cyclopamine also reduced the invasive ability of these cells by inhibiting the expression of
NK-κB, MMP2 and MMP9 proteins [3]. Taken together, these data suggest that cyclopamine could be a
promising therapeutic agent for the treatment of all subtypes of breast cancer [3].
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However, further consideration is needed for validating the usefulness of cyclopamine in treating
breast cancer, including dosage and duration of treatment. There is inconsistency in the published reports
on the dosage cyclopamine used. Several studies used relatively high doses of the drug for treating cell
lines, whilst others used much lower concentrations for treating the same cell lines. No real consensus
or justification has yet emerged on the selection of a specific dose [2,3,37].
Similarly, research on the use of cyclopamine in vivo has further indicated that its application could be
far from straightforward. Nowacka-Zawisza and Krajewska [72] reviewed the benefit of using hedgehog
inhibitors alone, or in combination with other agents in the treatment of triple negative breast cancer.
However, it is difficult to reach a high systemic levels of cyclopamine in vivo because it is potentially
toxic and has a relatively short half-life [73]. Conversely, Chai et al. reported that they did not
observe any effects of cyclopamine, even after 6 weeks of treatment, by histological examination of
vital organs [71].
Recently, Colavito et al. reported that the issue of drug resistance needs to be factored-in when
studying the effect of cyclopamine on breast cancer cell lines, either by elimination of drug from cells or
activating Hh signaling through alternative pathway (Figure 4B) [61]. Therefore, further complicating
the issue of finding an effective dose of cyclopamine for breast cancer in vitro as well as in vivo [74].
The other factor to consider is the duration of the treatment. Kameda et al. reported that cyclopamine
suppressed proliferation of cells after 72 h of incubation, although this effect was not detected after
24 h of incubation [2]. This is supported by data from a recent study that showed that the effect of
cyclopamine treatment on breast cancer cell lines started to show significant reduction after 5 to 10 days
of incubation [3].
Zhang et al. have demonstrated that cyclopamine used to inhibit Smo signaling must be
tested in resistant cell lines prior to sensitive ones, in order to eradicate any off-target effects [1].
Furthermore, treatment with cyclopamine or CUR0199691 (another Smo-antagonist) of Smo-expressing
and Smo-non-expressing cell lines showed that both agents were able to reduce tumor cell growth at high
dosage, regardless of Smo expression status, thus suggesting the presence of secondary target molecule
in breast cancer cell lines. This was confirmed by add-back of exogenous Shh, which did not antagonize
the effect of cyclopamine in those experiments [1]. As mentioned earlier, off-targets effects may occur at
higher doses of cyclopamine treatment—thus the reported effects in studies that treated cells with high
doses may not reflect specific effects on hedgehog signaling.
A selective oral inhibitor of SMO called LDE225 has shown an acceptable safety profile
after the phase I clinical trials on advanced solid tumors (basal cell carcinoma and relapsed
medulloblastoma) [75]. Both responsive cancer types are known to be significantly associated with
Hh pathway activation [75]. LDE225 showed greater efficacy than cyclopamine in the in vitro
reduction of cell proliferation and tumor growth arrest in melanoma [76]. In clinical trials, LDE225
produced a response in medulloblastoma and basal cell carcinoma, as well as disease stabilization in
lung adenocarcinoma, spindle cell sarcoma, breast cancer and one case of basal cell carcinoma in a
dose-escalation study [75]. LDE225 in combination with Docetaxel is currently in a phase I clinical
trial in patients with triple negative advanced breast cancer. The primary objective of this study is to
determine the maximum tolerated dose as well as the recommended phase II dose. In this study they
will assess the effectiveness of potential biomarkers by evaluating the activation of Hh signaling, the
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expression of Smo-related biomarkers and Hh target genes, as well as other, related, pathways [77].
However, no published work was found on the effect of LDE225 treatment on breast cancer in vitro or
in vivo at the time of submitting this review.
9. Conclusions
Breast cancer metastasis is the cause of death of almost all women diagnosed with this disease. Even
though the mortality rate has declined due the introduction of screening and targeted therapy, the survival
rates of some breast cancer subtypes remain low. Triple negative and basal-like breast cancer have the
worst prognosis, a low survival rate and increased chance of relapse [78]. Therefore, understanding the
process of cancer cell metastasis is vital to allow the development of targeted therapy.
The epithelial mesenchymal transition has been associated with human cancer metastasis in a number
of tissues, including breast cancer. Therefore, understanding the regulation of this process is important,
and Hh presents itself as a potential target. Despite some excellent published work, the role of the Hh
pathway in breast cancer remains to be fully elucidated. Many questions still need answering, such as the
dosage and treatment duration of the antagonizing agents. The molecular classification of the subtypes
of breast cancer in human clinical samples as well as in breast cancer cell lines needs taking into account
in studies of this pathway, as they have the potential to utilize Hh to their advantage in different ways
and may show different levels of reliance on Hh signals for tumorgenesis and progression. Furthermore,
as our understanding of stem cells, both in the normal tissue, and the various subtypes of tumor develop,
Hh may again appear as a prime target for therapeutic intervention in at least a subset of breast cancers.
There are apparent contradictions in some of the published work in this area, as there have been
in investigations of this pathway in multiple systems. However, an in-depth look at the detail of the
published work shows a clear variation between the various subtypes and further emphasizes the need
for a subtype-specific approach.
As mentioned previously, Shh, and its ligands, expression are correlated with ER-alpha breast cancers,
while Smo and Gli-1 are overexpressed in TNBC. Some studies correlated overexpression of Gli-1 to
ER-positive and TN subtypes of breast cancer. Though these data altogether may seem to contradict one
another, it would seem that the involvement of Hh signaling pathway in the pathogenesis of breast cancer
is mainly caused by misappropriation of these signals, rather than overexpression of a single component
of the pathway. Thus, the understanding of this variation in the expression and location of Hh pathway
component expression are critical prior to drawing conclusions about potential therapeutic targeting of
Hh in a specific group of breast cancer.
There remains a gap in our current understanding of the involvement of Hh signaling in breast cancer,
TN and BL in particular, even though there are many studies reporting the involvement of this pathway
as key regulator in normal prenatal and postnatal breast development. Hopefully, further study of the
association between the Hh pathway and breast cancer will yield new prognostic markers and yield new
targeted therapies.
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